Merck could keep its patent edge by shifting Keytruda cancer drug to a simple shot - Reuters
/cloudfront-us-east-2.images.arcpublishing.com/reuters/JXZIRTXOKNI3DMOLYXTN2RKUDM.jpg)
U.S. drugmaker Merck & Co (MRK.N) hopes to patent a new formulation of its $20 billion cancer immunotherapy Keytruda that can be injected under the skin, allowing it to protect its best-sel…